Tamoxifen
- Medical Review: Reshma L. Mahtani, DO
Tamoxifen is a hormonal therapy drug used in the treatment or risk reduction of hormone receptor-positive breast cancer. Tamoxifen can be used:
- To reduce the risk of hormone receptor-positive early-stage breast cancer coming back
- To treat hormone receptor-positive metastatic breast cancer
- To lower the risk of breast cancer in people who’ve never been diagnosed but who have a high risk for developing it
Tamoxifen is part of a class of drugs known as SERMs, or selective estrogen receptor modulators. SERMs are sometimes called estrogen blockers because they block estrogen from attaching to estrogen receptors on breast cancer cells. When tamoxifen blocks the receptors, estrogen is no longer able to attach and signal the cancer cells to grow.
How does tamoxifen work?
Tamoxifen works by blocking estrogen from binding to estrogen receptors in hormone receptor-positive breast cancer cells. Without the estrogen, the cancer cells can’t grow as well as they can with it.
Tamoxifen cannot be used to treat hormone receptor-negative breast cancer.
When is tamoxifen prescribed?
Tamoxifen may be prescribed to treat hormone receptor-positive breast cancer:
How is tamoxifen given?
Tamoxifen is taken daily as a pill (Nolvadex) and should be swallowed whole. A standard dose of tamoxifen is usually 20 milligrams a day. A liquid form of tamoxifen (Soltamox) is also available for people who have trouble swallowing. It’s important to take tamoxifen around the same time every day.
Most men who take tamoxifen to treat breast cancer take it alone. For women, risk of recurrence can play a role in whether tamoxifen is taken alone or with medicine that suppresses ovarian function.
Choice of hormonal therapy in early-stage breast cancer
Tamoxifen is approved for women of any menopausal status (premenopausal, perimenopausal, or postmenopausal). Pre- and perimenopausal women may be offered tamoxifen alone, tamoxifen in combination with medicine to suppress ovarian function, or a different type of hormonal therapy called an aromatase inhibitor in combination with ovarian function suppression medicine.
Medicines that suppress ovarian function are called gonadotropin-releasing hormone (GnRH) agonists (sometimes also called luteinizing hormone-releasing hormone agonists, or LHRH agonists). These drugs send a message to the brain that in turn stops the ovaries from producing estrogen, putting a premenopausal woman into menopause for as long as she is receiving the drug. Ovarian function can also be suppressed through oophorectomy, or surgical removal of the ovaries, which causes permanent menopause.
Research has shown that in premenopausal women with early-stage breast cancer, adding ovarian function suppression medicine to tamoxifen or to aromatase inhibitor treatment improves disease-free survival. However, adding this medicine to hormonal therapy can also increase side effects, so it’s important to talk with your healthcare team about what’s right for you.
Whatever your menopausal status, the choice of which therapy to use is based on risk of recurrence and whether you have been diagnosed with early-stage or metastatic breast cancer.
It’s important to know that it is not safe to get pregnant while taking tamoxifen, because tamoxifen can harm an unborn baby. But results from the POSITIVE trial show that most premenopausal women diagnosed with early-stage hormone receptor-positive breast cancer who want to have a baby can safely pause hormonal therapy temporarily to get pregnant without increasing the risk of breast cancer recurrence. Still, longer-term follow-up is needed to track how long the women in the study remain recurrence-free and how these numbers compare to women who don’t pause hormonal therapy. It’s important to make decisions with your care team about which treatment plan is best for you.
How long tamoxifen or other hormonal therapy is given
No matter what kind of hormonal therapy is recommended, in early-stage breast cancer, the type and duration of hormonal therapy is individualized based on tolerance of treatment, the risk of recurrence, and whether there may be a potential benefit to continue. Additional tests may be performed on the cancer that can help you and your healthcare team make decisions about the duration of hormonal therapy (5 versus 10 years). Here are some examples of different treatment durations:
- Some people may take tamoxifen for 5 years, followed by an additional 5 years of tamoxifen or an aromatase inhibitor.
- Other people may take tamoxifen or an aromatase inhibitor plus ovarian function suppression medicine for 5 years and then stop.
- Some people may switch to an aromatase inhibitor after 2 or 3 years of tamoxifen, for a total of 5 or more years of hormonal therapy.
In metastatic breast cancer, tamoxifen may be taken as long as it is working to treat the cancer. Learn more about treatment for hormone receptor-positive metastatic breast cancer.
Low-dose tamoxifen, or babytam
Low-dose tamoxifen, sometimes called babytam by doctors, is also used in certain situations and can help reduce the side effects of tamoxifen. A recent study of low-dose tamoxifen used a 5-milligram dose. This trial did not compare the 5-milligram dose to the standard 20 milligrams and did not include people with invasive breast cancer. However, it did provide some assurance that babytam may be used as a treatment option for women who are having difficulty tolerating the standard dosing and are taking tamoxifen for the following reasons:
- To reduce the risk of breast cancer recurrence in people who’ve been diagnosed with ductal carcinoma in situ (DCIS), which is stage 0 noninvasive breast cancer.
- As preventative therapy to reduce the risk of developing breast cancer in people diagnosed with lesions that are benign but increase the future risk for developing breast cancer, such as:
- Atypical ductal hyperplasia (ADH), which is abnormal cell growth in a breast duct
- Lobular carcinoma in situ (LCIS), which is abnormal cell growth in a breast lobule
Side effects
As with any medicine, taking tamoxifen can cause side effects. Each person taking tamoxifen has their own unique experience of side effects. For some people, they may be manageable. For other people, they can be very difficult. It’s important to talk with your doctor about what to expect and ways to prevent or manage side effects. Common tamoxifen side effects include:
- Fatigue
- Menopausal symptoms such as hot flashes and vaginal dryness
- Nausea
- Hair thinning
- Loss of interest in sex
- Loss of sexual ability (in men)
- Difficulty with memory and concentration, especially with long-term use
Taking tamoxifen also has helpful side effects that are not related to cancer. These include:
- Preventing bone loss in postmenopausal women
- Lowering total cholesterol levels
Rare side effects
Blood clots are a rare but serious side effect of tamoxifen. They usually occur in the leg, but blood clots can travel from the legs to the lungs. Signs of a blood clot in the leg can include pain, warmth, and/or swelling of the leg. Signs of a blood clot in the lungs can include shortness of breath, chest pain, or fever. If you experience any of these, it is important to seek emergency medical attention. Blood clots can also cause a stroke.
People who have a high risk of blood clots are those with a family history of blood clots, who are smokers, who are older, and those who have an inactive lifestyle and other medical problems.
Additional rare side effects of tamoxifen include:
- Mood changes
- Bone loss in premenopausal women
- Endometrial cancer or uterine sarcoma, a rare uterine cancer
- Cataracts, or problems with vision
- Liver problems
- Depression
Tamoxifen may lead to depression as a side effect in some people. If you experience depression and notice worsening symptoms, especially thoughts of self-harm, let your physician know right away. While aromatase inhibitors may not commonly trigger depression, pre-existing depression can intensify because you're dealing with a lot of issues related to cancer. It’s very important to ask for help, because there's a lot of support available. Antidepressants, counseling, and exercise are all options that can relieve symptoms. Don't suffer in silence; talk with your provider about support that works for your individual needs.
How effective is tamoxifen for breast cancer?
In women diagnosed with early-stage breast cancer or who have a high risk of developing breast cancer, tamoxifen has been shown to:
- Reduce the risk of recurrence up to 50% in the first 5 years of treatment and up to 30% in the next 5 years
- Reduce the risk of developing invasive breast cancer by about 50% in postmenopausal women who are at high risk
- Reduce the risk of developing breast cancer for at least 20 years after 5 years of treatment
Taking other medicines with tamoxifen
Some medicines may affect how well tamoxifen works. For example, CYP2D6 inhibitors are medicines that prevent a liver enzyme called CYP2D6 from converting tamoxifen into its active form. These kinds of drugs may stop tamoxifen from working as well as it could. Some antidepressants are CYP2D6 inhibitors, including the following:
- Bupropion (Wellbutrin)
- Duloxetine (Cymbalta)
- Fluoxetine (Prozac)
- Paroxetine (Paxil, Seroxat)
- Sertraline (Zoloft)
Other medicines that inhibit CYP2D6 include:
- Cinacalcet (Sensipar), which is used to treat hyperparathyroidism in people with kidney disease
- Quinidine, which is used to treat irregular heart rhythms
- Diphenhydramine (Benadryl), which is used to treat allergies
- Cimetidine (Tagamet), which is used to treat stomach ulcers and heartburn
If tamoxifen has been recommended for you, tell your doctor about all medicines and supplements you take. If you need to take a medicine that inhibits CYP2D6, discuss the risks with your care team. There may be other hormonal therapy options for you.
Frequently asked questions
Can I become pregnant while taking tamoxifen?
Yes, it is possible to become pregnant while taking tamoxifen; taking tamoxifen does not prevent pregnancy. However, tamoxifen can harm a developing baby and cause birth defects. If you are sexually active and taking tamoxifen, it is very important to use nonhormonal birth control, such as condoms. This applies even if you’re a woman whose menstrual cycle has stopped due to other treatments, or if you are a man who does not produce sperm.
Is it safe to become pregnant while taking tamoxifen?
No. Tamoxifen may cause birth defects in an unborn baby.
Is it safe to breastfeed while taking tamoxifen?
No. People who are taking tamoxifen should not breastfeed.
What contraceptive methods should I use while taking tamoxifen?
Nonhormonal contraceptives should be used while taking tamoxifen, and you should continue to use them for 2 months after you stop taking tamoxifen. These include condoms, IUDs, and diaphragms. Talk to your doctor about which nonhormonal contraception is right for you.
How long do I have to take tamoxifen?
Tamoxifen is typically taken for 5 years, but some people take it for a longer duration depending on the risk of recurrence and tolerance to treatment.
Is tamoxifen covered through insurance?
Tamoxifen may be covered through insurance. Ask your insurance provider or talk to your care team if you need help with additional resources.
Can tamoxifen cause neuropathy?
Neuropathy is not a common side effect of tamoxifen, but some people do experience muscle weakness as a side effect.
Can I choose not to take tamoxifen?
Tamoxifen is not the only medicine used to help treat or reduce the risk of breast cancer or cancer recurrence. You have choices, and your care team can help you decide the treatment plan that is right for you. Talk with your team about the most effective treatments for you.
What does tamoxifen do to the body?
Tamoxifen blocks estrogen receptors. Without estrogen, the cancer cells that receive growth signals from estrogen may not be able to survive. Tamoxifen can also cause side effects, such as:
- Fatigue
- Menopausal symptoms such as hot flashes and vaginal dryness
- Nausea
- Hair thinning
- Loss of interest in sex
- Loss of sexual ability (in men)
If tamoxifen has been recommended for you, talk with your care team about ways to manage or prevent side effects.
Can tamoxifen cause neurological problems?
As mentioned above, tamoxifen does not cause neurological issues such as neuropathy. There is evidence that tamoxifen can cause cognitive impairment, such as memory difficulty.
How long does it take for your body to get used to tamoxifen?
How the body adjusts and responds to tamoxifen is highly individual. It’s important to talk with your healthcare team about what to expect.
Do the side effects of tamoxifen start immediately? How long do they last? Do they get worse over time?
Tamoxifen side effects are experienced differently for each person. There are many ways to manage side effects. Ask your healthcare team about side effects you might experience and strategies to manage them.
Related news
- Enfortumab vedotin shows anti-tumor activity but does not meet trial goals | ASCO 2024
- Abemaciclib shows small benefit after a prior CDK 4/6 inhibitor stops working | ASCO 2024
- Trastuzumab deruxtecan beats chemotherapy—even in HER2-ultralow MBC | ASCO 2024
- Inavolisib delays PIK3CA-mutated MBC progression by almost eight months | ASCO 2024
Related videos
View allStay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical